Guardant Health receives coverage for Guardant Reveal from Geisinger

Guardant Health announced that Geisinger Health Plan now offers coverage for the Guardant Reveal minimal residual disease MRD test. Guardant Reveal is a blood test that detects circulating tumor DNA ctDNA in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing. Geisinger is providing coverage for the Guardant Reveal test for individuals with stage II or III colorectal cancer after curative treatment to inform physician decisions about post-treatment therapy and to monitor for disease progression, recurrence or relapse. The frequency of testing covered is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer. It includes the initial ctDNA test 4 to 6 weeks after surgery and thereafter every 3 to 6 months for the first two years, and every 6 to 12 months for the following 3 years.